The global healthcare landscape is increasingly focused on preventive medicine and personalized therapies to combat the rising incidence and costs of chronic diseases, especially cardiovascular conditions. As populations age, the demand for effective interventions that improve quality of life and reduce long-term care burdens is intensifying. This technology aligns perfectly with this trend by offering a proactive approach to myocardial health, potentially reducing the need for more invasive or costly treatments later. Regulatory bodies are also encouraging innovations that demonstrate clear patient benefits and economic efficiencies.
Maximize Myocardial Cell Protection: This pharmaceutical composition, containing a compound of specific chemical formula (I), effectively suppresses damage to myocardial cells and supports functional maintenance. This could open new avenues for inhibiting the progression and preventing heart diseases not adequately addressed by existing therapies.
Stable IP Foundation for Business Development: This patent was granted after rigorous examination, overcoming challenges from five prior art documents. This establishes a robust and validated IP right, providing licensees with a secure foundation for business development.
Long-Term Market Exclusivity: With a remaining patent term until 2040, licensees can develop products, launch them, and establish a strong market position while deterring competitors, ensuring a strategic advantage.
This patent protects a pharmaceutical composition containing specific compounds for myocardial cell protection, defined by 12 broad and multifaceted claims. It was granted after successfully overcoming multiple office actions with precise amendments and arguments, indicating a robust and difficult-to-invalidate scope of protection.
This patent focuses on the composition itself. White space exists in developing novel drug delivery systems for this compound or exploring combination therapies with existing cardiovascular treatments to achieve synergistic effects.
Assuming total annual cardiovascular disease-related healthcare costs of ~$13.5B (AI est.), and an average treatment cost of ~$6.5K/year (AI est.) for the target patient group. If this technology inhibits disease progression in 5% of target patients, reducing their treatment costs by 50%, the estimated annual healthcare cost reduction could be ~$16.5M (AI est.) (calculated as ~$13.5B (AI est.) × 5% × 0.5% × ~$6.5K/year (AI est.) / ~$6.5K/year (AI est.)).
X: Durability of Therapeutic Effect
Y: Reduced Side Effect Risk